New ProductsThroughout 2022, the epidemic situation in Vietnam has been basically under control, but there are still many fluctuations and difficulties for the economy and market. In this context, OPC Pharma continued to develop sustainably, with a significant increase in revenue and profit exceeding the targets set in the 2022 plan. Specifically: revenue reached VND1,194 billion, profit before tax was VND180 billion.
The meeting also proceeded with the election of 2 additional members of the Board of Management (BOM) and 1 additional member of the Board of Supervisors (BOS) for the term 2021-2026 after the resignation of Mr. Le Van Son – Chairman of the BOM, Mr. Nguyen Hai Duong – BOM member and Mr. Nguyen Trung Thanh – BOS member. The results of the additional election, the following gentlemen were elected to the BOM and BOS with a high percentage of votes:
- Mr. Hoang Le Son – Chairman of the BOM
- Mrs. Pham Thi Xuan Huong – CEO, BOM member
- Mr. Nguyen Anh Vu – Member of the BOS
Continuing to promote the achievements, the management team and employees of OPC are determined to overachieve the production and business plan and key tasks in 2023.
Some images at the meeting:
